RE:RE:RE:G12D/G12V KRAS mutation in PC & CRC patients respond to PelaJanuary 10. 2024 - Elicio Therapeutics, the makers of ELI-002, a new vaccine that works by targeting two genetic mutations of KRAS genes, specifically KRAS G12D and KRAS G12R, and built of their Amphiphile (AMP) platform, reported on a phase 1 trial in pancreatic and colorectal cancers, that was conducted by researchers at The University of Texas MD Anderson Cancer Center.
Reasearchers found that participants needed to hit a certain threshold for their T cell response to see benefits. Participants who had a T cell response higher than the median did not have a recurrence of cancer, although follow-up is ongoing. Meanwhile, those who did not meet this threshold had an average recurrence of cancer within 4 months.
https://ascopubs.org/doi/abs/10.1200/JCO.2023.41.16_suppl.2528
https://elicio.com/pipeline/eli-002/